Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + CAPEOX ± bevacizumab in first-line advanced colorectal cancer by MMR/APC subtype
ChiCTR2500106197Phase 4Not yet recruiting
- Sponsor
- Ganzhou People's Hospital
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of iparomlimab + tuvonralimab in colorectal cancer (CRC) (4 arms), sponsored by Ganzhou People's Hospital. Primary endpoint: Objective Response Rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500106197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106197.